All articles by Phillip Broadwith – Page 17
-
Business
Bayer to close polycarbonate plant and cut 90 jobs
Firm has already shut Chinese plant, and will also sell off businesses in Australia and New Zealand
-
Business
Inhaled insulin approved in US
European committee recommends approval for generic long-acting insulin
-
Business
Affymax folds after drug withdrawal
Unexplained allergic reactions to anaemia drug prompt firm to dissolve
-
Business
Biotech bounced back in 2013, says report
R&D investment increasing, but industry needs to use its cash more wisely
-
Business
Shire fends off AbbVie takeover bid
Board says deal undervalues the company and its growth potential
-
Business
Medtronic to buy Covidien for $43bn
Tax inversion deal continues consolidation theme among medical device makers
-
Business
Novo Nordisk to create 6000 jobs by 2022
Half of the new Danish employees will be in R&D roles
-
Business
Merck & Co bolsters hepatitis C pipeline with Idenix acquisition
Early-stage drugs complement Merck’s own developmental portfolio
-
Business
Data sharing helps firms reduce Reach animal testing
Alternative in vitro methods slowly gaining traction for some tests
-
Business
Generics giants jostle over pain drug
Mylan and Actavis contest Teva’s generic celecoxib exclusivity
-
Business
Drug companies rapped for anticompetitive behaviour
Italian authorities demand €1.2 billion in damages from Roche, Novartis and Pfizer
-
Business
Nano risk register not necessary, says BASF
Reach covers the relevant information, and a register risks attracting unwarranted stigma
-
Business
Boehringer to settle blood thinner drug suits for $650m
Company confident in drug safety but says court cases are too risky
-
Business
Time called on Pfizer–AstraZeneca deal
Pfizer could make a fresh approach after six months under City takeover rules
-
Business
Mitsui continues reinvention efforts with two deals
Japanese firm drops organic acids in favour of lens materials
-
Business
Novartis enhances its focus with eyecare deal
Swiss firm buys rights to wet AMD drug from Ophthotech for up to $1bn
-
Business
AstraZeneca refuses Pfizer’s ‘final’ offer
Pfizer pledges not to make hostile bid direct to shareholders
-
Business
Lilly protests $450m Brazilian fine
Firm says chemicals employees were allegedly exposed to were never used at site
-
Business
Chinese police hand GSK bribery case to prosecutors
Investigation alleges senior manager ordered staff to hand out bribes